Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $36.46 USD
Change Today +0.10 / 0.28%
Volume 152.8K
OFIX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

orthofix international nv (OFIX) Snapshot

Open
$36.47
Previous Close
$36.36
Day High
$36.83
Day Low
$36.29
52 Week High
04/2/15 - $38.94
52 Week Low
10/16/14 - $26.96
Market Cap
683.8M
Average Volume 10 Days
77.4K
EPS TTM
$0.40
Shares Outstanding
18.8M
EX-Date
--
P/E TM
91.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for ORTHOFIX INTERNATIONAL NV (OFIX)

orthofix international nv (OFIX) Related Businessweek News

No Related Businessweek News Found

orthofix international nv (OFIX) Details

Orthofix International N.V., a medical device company, designs, develops, manufactures, markets, and distributes medical devices used principally by musculoskeletal medical specialists for spine and orthopedic applications. The company operates in four segments: BioStim, Biologics, Extremity Fixation, and Spine Fixation. The BioStim segment offers a range of devices for use as adjunctive treatment to enhance fusion success in cervical and lumbar spine fusion, as well as a therapeutic treatment for non-healing fractures outside of the spine. The Biologics segment provides a portfolio of regenerative products that allow physicians to treat a range of spinal and orthopedic conditions under the Trinity Evolution and Trinity Elite names. The Extremity Fixation segment offers orthopedic products used in fracture repair, deformity correction, and bone reconstruction. The Spine Fixation segment provides a range of implant products used in surgical procedures of the spine. The company markets and distributes its products directly to hospitals, doctors, and other healthcare providers in the United States, the United Kingdom, Italy, Germany, Switzerland, Austria, France, Belgium, Brazil, Australia, and Puerto Rico, as well as through independent distributors, sales representatives, and affiliates in other markets. Orthofix International N.V. was founded in 1987 and is headquartered in Willemstad, Curaçao.

889 Employees
Last Reported Date: 03/31/15
Founded in 1987

orthofix international nv (OFIX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $452.8K
President of Global Extremity Fixation
Total Annual Compensation: $437.2K
Chief Strategy Officer
Total Annual Compensation: $460.0K
Chief Administrative Officer, General Counsel...
Total Annual Compensation: $455.0K
Compensation as of Fiscal Year 2013.

orthofix international nv (OFIX) Key Developments

Orthofix International N.V. Receives Letter From Nasdaq

On April 1, 2015, Orthofix International N.V. received a letter from the Nasdaq Stock Market stating that a Nasdaq Hearings Panel had granted the company’s request for relief from delisting provided that the company completes the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2014 (2014 Form 10-K) by April 30, 2015. As previously disclosed, the filing of the 2014 Form 10-K has been delayed while the company worked to complete a restatement of its consolidated financial statements for the fiscal years ended December 31, 2013, 2012 and 2011 (including the interim quarterly periods contained within the fiscal years ended December 31, 2013 and 2012) and the fiscal quarter ended March 31, 2014. These restated financial statements were completed and filed with the Securities Exchange Commission on March 31, 2015. In addition, on March 31, 2015, the company filed its quarterly reports on Form 10-Q for the fiscal quarters ended June 30, 2014 and September 30, 2014, which had also been delayed while the company worked to complete this restatement. The company is working expeditiously to complete the 2014 Form 10-K, and currently expects to file it on or prior to April 30, 2015. In the event that the company’s expected timing changes, the company has agreed to promptly update the Hearings Panel.

Orthofix International N.V. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Orthofix International N.V. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported net sales of $100,994,000 against $91,806,000 a year ago. Operating income was $6,508,000 against operating loss of $14,101,000 a year ago. Income before income taxes was $4,791,000 against loss before income taxes of $16,121,000 a year ago. Net income from continuing operations was $28,000 or $0.00 per basic and diluted share against net loss from continuing operations of $16,504,000 or $0.91 per basic and diluted share a year ago. Net income was $452,000 or $0.02 per basic and diluted share against net loss of $18,836,000 or $1.04 per basic and diluted share a year ago. Adjusted net income from continuing operations was $3.3 million, or $0.17 per diluted share, compared to $4.0 million, or $0.22 per diluted share, in the third quarter of 2013. Adjusted EBITDA from continuing operations was $17.8 million for the period, or 17.6% of sales, compared to $14.4 million, or 15.7% of sales, for the same period in the prior year. The increase in adjusted EBITDA was due primarily to the higher sales mix from the BioStim SBU compared to the prior year. For the full year, the company reported net sales of $301,993,000 against $291,725,000 a year ago. Operating income was $13,183,000 against operating loss of $1,113,000 a year ago. Income before income taxes was $10,597,000 against loss before income taxes of $573,000 a year ago. Net income from continuing operations was $1,346,000 or $0.07 per basic and diluted share against net loss from continuing operations of $8,566,000 or $0.45 per basic and diluted share a year ago. Net loss was $2,739,000 or $0.15 per basic and diluted share against $18,400,000 or $0.97 per basic and diluted share a year ago. Adjusted net income from continuing operations was $11.1 million, or $0.60 per diluted share, compared to $14.2 million, or $0.75 per diluted share, for the same period in the prior year. Adjusted EBITDA from continuing operations was $49.0 million for the period, or 16.2% of sales, compared to $47.4 million, 16.2% of sales, in the same period in the prior year. The increase in adjusted EBITDA on a dollar basis was due to the $10.3 million increase in net sales. Net cash provided by operating activities was $35,966,000 against $51,903,000 a year ago. Capital expenditures for property, plant and equipment were $11,324,000 against $19,427,000 a year ago. Capital expenditures for intangible assets were $170,000 against $4,525,000 a year ago.

Orthofix International N.V. Receives Additional Non-Compliance Notice

On March 18, 2015, Orthofix International N.V. received an anticipated letter from NASDAQ noting that the 2014 Annual Report on Form 10-K had not been filed by its due date with the SEC on March 16, 2015 and, as such, represented an additional basis for non-compliance with Listing Rule 5250(c)(1). The company continues to work to complete the procedures needed to file its two delayed quarterly reports and the amended reports containing its restatement for prior periods, as well as its 2014 Annual Report on Form 10-K. As requested by the letter from NASDAQ, the company will be providing a written update to the Hearings Panel regarding these matters on or before March 25, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OFIX:US $36.46 USD +0.10

OFIX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AngioDynamics Inc $17.10 USD +0.25
Merit Medical Systems Inc $20.58 USD +1.34
NxStage Medical Inc $19.40 USD +0.04
RTI Surgical Inc $5.86 USD +0.09
Tornier NV $26.25 USD +0.01
View Industry Companies
 

Industry Analysis

OFIX

Industry Average

Valuation OFIX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.7x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ORTHOFIX INTERNATIONAL NV, please visit www.orthofix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.